about
Erythropoietin and the use of a transgenic model of erythropoietin-deficient miceErythropoietin improves the survival of fat tissue after its transplantation in nude miceWhat's New in Traumatic Brain Injury: Update on Tracking, Monitoring and TreatmentErythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice.Retinopathy of prematurity: current concepts in molecular pathogenesis.Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.Erythropoiesis and iron sulfur cluster biogenesis.Erythropoietin protects against diabetes through direct effects on pancreatic beta cellsAngiogenesis in diabetes and obesityAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinomaErythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastomaErythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.Role of erythropoietin in the brainErythropoietin deficiency decreases vascular stability in mice.Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma developmentErythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis.Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis.Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator).Dual inhibiting senescence and epithelial-to-mesenchymal transition by erythropoietin preserve tubular epithelial cell regeneration and ameliorate renal fibrosis in unilateral ureteral obstruction.Histological quantification of angiogenesis after focal cerebral infarction: a systematic review.Emerging technologies in the delivery of erythropoietin for therapeutics.Histological quantification of brain tissue inflammatory cell infiltration after focal cerebral infarction: a systematic review.Erythropoietin in stroke: quo vadis.Erythropoiesis-stimulating agents and heart failure.The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment.Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection.Liver function and anemia pathogenesis in Iranian traditional medicine.Asialoerythropoietin prevents contrast-induced nephropathyHepatic erythropoietin response in cirrhosis. A contemporary review.Hypoxia in Atherogenesis.The neuroprotective effect of recombinant human erythropoietin via an antiapoptotic mechanism on hypoxic-ischemic brain injury in neonatal rats.Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium.Erythropoietin neuroprotection with traumatic brain injuryEffects of recombinant human erythropoietin on revascularization of full thickness skin grafts in ratSimvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes.Erythropoietin: a multimodal neuroprotective agent.Enalapril alters expression of key growth factors in experimental diabetic retinopathy.Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits.
P2860
Q28075785-5A5991EB-1B16-4690-A66E-71349F145846Q28748456-6F3A9AD9-DB67-4774-9BFB-BC017E5AFFC6Q30959630-22EB398B-2E4B-40D3-BA39-DC160743C4FDQ33262324-B505FD45-9FA7-4EEB-9FDA-9FBFBA5D73C2Q33606227-B779ECF9-1C3F-4CCD-918C-0378E800F844Q34006181-5421A021-CB9A-47E3-882E-ADBA79F8973EQ34127573-14DE071B-08DC-434C-AC53-F82CF9454C82Q34420833-0ABA089C-A70D-407D-A41F-554C786B1BD8Q35153884-336A3746-0E81-41E3-AA10-569563AE2F25Q35205410-B002B053-ADB0-4ADB-9794-19E9490D7722Q35404296-42D3C249-CED7-4C99-8449-EA66D4161502Q35839982-4ED3F826-0217-4636-824D-6AF9FFA55371Q35840006-A3BDBDC4-5BFB-47C8-926E-BBE278DC9F05Q36153802-AFBE838D-9DB1-46C7-9EB2-2874E6180744Q36404124-AC8E478A-2C84-4FEE-9031-7D9043BEDD6CQ36431079-1CF2D5C4-3C62-46D3-A27D-DE8CD727A848Q36611934-2C5F46C9-D9BE-46B7-A74B-FB15A39964E5Q36645651-7FC8CB60-2CEA-41AD-83EE-04639DA97628Q36840259-A2B6F750-3A43-4003-B714-D8B748C278BCQ36920419-073C4618-EA1A-4C85-9E6C-13ECD6FC5C72Q37367044-8B61D0CB-373F-45E4-BDC9-C36E6A6BA126Q37482346-913862CB-DA2A-48B7-8615-752462662FBFQ37646523-1D4C1261-B348-4399-B759-5838ACBCBF1EQ37672487-363C6161-3642-4D01-A981-039DAB0D5C92Q37731533-02898BEB-C80B-4ADF-AB06-D8C6774A311CQ37802925-6DF06480-9449-4DCD-9D79-B981F6F08775Q38110390-972F03E8-8FAD-421A-99E7-48CB27CE7CADQ38255341-F2C03C4F-094D-4B58-AC49-3EC9E1FF56E0Q38374851-EA65E711-F7BF-4DC3-8A29-C2BA7EA1FFF3Q38624703-72D2BCDC-5760-4E48-9DD3-4841A766B4E4Q38751471-56BD70BC-EDBA-42BE-B823-02EF7A35867CQ38939115-9CFC2C57-29A6-447A-9F08-04D7743E69A7Q41239132-DDD70832-BA7A-49B3-98A4-5FD0A69C89C5Q41836951-54E662DC-960C-4595-964E-24D1A13FDC75Q42226775-BBBFB249-0FE8-469F-ABF3-1F0F0E61B847Q42721269-509945C3-C042-4374-B0E3-185670F4869FQ42915712-E1D2C591-2C7C-461B-BCC0-46F5AD3A7B13Q42922791-0DCBD6A1-03B2-4E6D-BD7C-2813DAD91108Q43230857-11A1C472-7107-45E1-9F33-84955F50512BQ46292739-78DEB0B7-D1F2-4D60-8208-F16736E94EDD
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Erythropoietin as an angiogenic factor.
@ast
Erythropoietin as an angiogenic factor.
@en
type
label
Erythropoietin as an angiogenic factor.
@ast
Erythropoietin as an angiogenic factor.
@en
prefLabel
Erythropoietin as an angiogenic factor.
@ast
Erythropoietin as an angiogenic factor.
@en
P2093
P1476
Erythropoietin as an angiogenic factor
@en
P2093
P304
P356
10.1046/J.1365-2362.2003.01245.X
P577
2003-10-01T00:00:00Z